Stanford’s Professor John Cooke Joins Pluristem’s Scientific Advisory Board

Pluristem Therapeutics Inc. (NasdaqCM:PSTI)(DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that John Cooke, MD, PhD has accepted an appointment to the Company’s Scientific Advisory Board to assist Pluristem with its efforts to further develop the Company’s product candidates and give patients a better chance.

Dr. Cooke, Professor of Medicine, Division of Cardiovascular Medicine at the Stanford School of Medicine, as well as Associate Director (Education and Training) of Stanford’s Cardiovascular Institute in Palo Alto, California, said: "Scientific discoveries of today are the medicine of tomorrow. I am pleased to join Pluristem’s Scientific Advisory Board, since I believe that the scientists and management team at Pluristem use innovative approaches to make breakthrough discoveries in the cell therapy arena as well as to build a biotechnology company with sound business values.”

Zami Aberman, Pluristem’s President and CEO, said: "We are proud that Dr. Cooke has accepted a position on what has become a world renowned Scientific Advisory Board at Pluristem. Dr. Cooke’s expertise in angiogenesis and wound-care will create significant synergism together with the knowledge and expertise of our current Board members.”

Dr. Cooke received his MD degree from Wayne State University, Detroit, and his PhD from the Mayo Graduate School of Medicine, Rochester, MN, and was a faculty member of Harvard Medical School prior to his recruitment to Stanford University. He serves on the editorial boards of several cardiovascular journals including Circulation, and is past-president of the Society for Vascular Medicine. Dr. Cooke’s area of research interest is in angiogenesis and he has served as the Principal Investigator for numerous clinical trials.

Detailed biographies of each member of the Advisory Board are available on our website at: Pluristem’s Advisory Board, the content of which is not part of this press release.

About Pluristem

Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products derived from human placenta, a non-controversial, non-embryonic, adult stem cell source. The PLacental eXpanded cell products (PLX) are stored off-the-shelf, ready-to-use, and require no histocompatibility matching.

These placental adherent stromal cells (ASCs) are expanded in the Company's proprietary PluriX^TM 3D bioreactor system, which provides a 3D microenvironment that enables large-scale growth of these cells without the need for supplemental growth factors or other exogenous materials. PLX cells are immune privileged, possess immunomodulatory properties, and are expanded in vitro without showing signs of phenotypic or karyotypic changes. Pluristem believes that the PLX cells’ mechanism of action may be related to the secretion of cytokines and/or other potent immune modulators.

Pluristem's first product, PLX-PAD (for the treatment of Peripheral Artery Disease), received FDA clearance to begin a "First-In-Human” placental-derived mesenchymal-like stromal cell clinical trial.

The Company's additional product candidates include PLX-IBD, targeting Inflammatory Bowel Disease (IBD), which includes Crohn’s disease and Ulcerative Colitis; PLX-MS, targeting Multiple Sclerosis; PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; and PLX-STROKE, targeting ischemic stroke.

Pluristem has offices in the USA with research and manufacturing facilities in Israel.

See our product animation on YouTube: Animation, the content of which is not part of this press release.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. For example, when we speak about our efforts to further develop our product candidates and give patients a better chance, we are using forward-looking statements. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.

For more information visit our website at www.pluristem.com, the content of which is not part of this press release.